Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etozoline is a long-acting loop diuretic that has been marketed in Europe under the brand names Diulozin, Elkapin, and Etopinil. It is a small molecule drug used primarily for its diuretic effects in the management of conditions such as congestive heart failure. Etozoline acts by inhibiting sodium and chloride reabsorption in the thick ascending limb of the loop of Henle in the kidney nephron. This leads to increased excretion of water and electrolytes (notably sodium and chloride), resulting in diuresis. Etozoline is rapidly metabolized to its active metabolite ozolinone[1][2][3]. Additionally, studies suggest that its vasodilating action may be mediated by inhibition of calcium influx into smooth muscle cells[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etozoline.